Our team’s recent blog on the impact of COVID-19 on competition law in the UK pharma sector, shed light on the temporary framework issued by the European Commission and how it intends to assess antitrust issues related to business cooperation in responding to COVID-19.

The Commission’s decision to resume the issuance of comfort letters (if only temporarily) reflects the severity of the COVID-19 crisis and recognises the importance of enabling cooperation between companies to the full extent permitted by competition law. It intends to assess antitrust issues related to business cooperation in responding to COVID-19.

On 29 April 2020 the Commission published the text of the comfort letter it had sent to Medicines for Europe (MfE) on 8 April. Read the full article on our competition law blog, The CLIP Board – ‘European Commission resurrects comfort letters to combat COVID-19.’